Vir Biotechnology, Inc.

499 Illinois Street, Suite 500, San Francisco, CA 94158

4

BPI
Financial Rating

3.5

BPI Stakeholder Rating

3

BPI Social Responsibility Rating

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

3.5

Overall Excellence Rating

Industry

Healthcare

Category

Biotech & Pharmaceuticals

ESG/Ethical Impact

Vir Biotechnology’s research and development efforts in infectious diseases could contribute to environmental sustainability indirectly by addressing health issues that impact communities and reduce the overall burden on healthcare systems. Sustainable Practices: While the biotechnology industry’s direct environmental impact might be limited, the company may implement sustainable practices within its operations, such as energy-efficient facilities and responsible waste management.Public Health Impact: Vir Biotechnology’s core mission to develop antiviral therapies directly impacts global public health. Their work in infectious diseases addresses critical health challenges and helps prevent and treat serious viral infections. Pandemic Preparedness: The company’s research and development initiatives align with global efforts to enhance pandemic preparedness, contributing to a safer and healthier world. Collaboration with global health organizations and governments could enhance the reach of Vir’s therapies and contribute to global health goals.Clinical Standards: As with any biopharmaceutical company, adhering to rigorous ethical and clinical standards in drug development is crucial. Vir Biotechnology’s commitment to patient safety and ethical research practices is paramount. Vir Biotechnology’s governance framework and policies likely emphasize transparency, accountability, and ethical behavior, building trust with stakeholders and investors.Vir Biotechnology’s financial sustainability comes from the development and potential commercialization of antiviral therapies. Investor Relations: The company’s ESG efforts can influence investor perception, especially for those seeking investments aligned with ethical healthcare innovations. The company’s ESG initiatives can resonate with investors interested in both financial returns and ethical medical advancements.Vir’s focus on infectious diseases has the potential to improve healthcare access for underserved populations worldwide, providing treatments for diseases that disproportionately affect vulnerable communities. The company’s ESG efforts can impact investor perception. Investors who prioritize both financial returns and positive societal impact may find alignment with Vir’s mission and values. Vir Biotechnology’s antiviral therapies directly benefit patients by providing treatments for serious infectious diseases that can significantly improve health outcomes.

Eligible Awards

Coming Soon





Claim Your Award Badges

Do you work with Us

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer.

Awards Received

2023

Revenues

$1,600,000,000.00

Website Traffic

Employee Rating

3.5

Customer Rating

3.5

Company Size

100-1000

ESG Risk Rating

3

We’re Happy to Help.

Do you have questions about your ranking, our projects, or why you’re not on the list?
Scroll to Top

Excellence In My Industry

This badge tells your customers, employees, partners, and other stakeholders that your company has met the criteria of our excellence certification in best practices across all pillars of business in your specific industry – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.

Best Practice Certified

This badge tells your customers, employees, partners, and other stakeholders that your company has met the criteria of our excellence certification in best practices across all pillars of business – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.

Best of Best Practices

This badge tells your customers, employees, partners, and other stakeholders that your company is one of the top 20 companies in your industry that has met the criteria for our excellence certification in best practices across all pillars of business – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.

Newsweek Excellence 1000

This badge tells your customers, employees, partners, and other stakeholders that your company is one of the Top 1000 companies that demonstrate excellence across all pillars of business – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.